Acthar Gel Medicaid Rebates: Mallinckrodt Loses 'Gamble' Over FDA's NDA Numbering System
Executive Summary
Mallinckrodt must pay $650m in retroactive Medicaid rebate payments; case shows how application filings can impact CMS reporting requirements and price-based reimbursements.
You may also be interested in...
Why Is Congress Targeting These Six Medicines In Drug Price Hearing?
Revlimid, Copaxone, Sensipar, Enbrel, Acthar Gel and Gleevec will be the subject of a US House Committee on Oversight and Reform in an upcoming drug price hearing.
Sawai’s Upsher-Smith Takes Aim At US Corticotropin Opportunity
Upsher-Smith Laboratories, the US arm of Japan’s Sawai Pharmaceutical, has another challenging project in the pipeline with an agreement to develop and market a follow-on version of Mallinckrodt’s Acthar Gel (corticotropin). The Japanese firm revealed Upsher-Smith’s latest finances as it revealed first-quarter financial results.
Keeping Track: US FDA Okays BMS’ Zeposia In MS, Nixes Lilly/BI’s Empagliflozin For Type 1 Diabetes
The latest drug development news and highlights from the Pink Sheet US FDA Performance Tracker.